Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces today that its p ...

Our Bureau, Bengaluru Tuesday, February 25, 2025, 14:45 Hrs [IST] ...

Venus Remedies is collaborating with UK-based Infex Therapeutics for the clinical development of MET-X, a ...

Venus Remedies has partnered with Infex Therapeutics to develop MET-X, an innovative metallo-beta-lactamase inhibitor, to ...

The deal grants Venus Remedies the rights to develop, register, and commercialise MET-X, a novel metallo-beta-lactamase (MBL) ...

Venus Remedies rose 2.15% to Rs 313.65 after the company said it secured exclusive in-licensing rights from UK's Infex Therapeutics to develop and commercialize MET-X in India.

The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.

The other leading molecules in the same segment, like rosuvastatin and telmisartan, continued to grow in line with the ...

Analysis of data from 537 US hospitals reveals that ceftolozane-tazobactam and ceftazidime-avibactam are the most frequently ...